IFW

OCI 9 1 1003 STRANSMITTAL LETTER (General - Patent Pending)

Docket No. DI-5924

In Re Application of

Zieske et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/628,065	July 25, 2003	E. Peselev	29200	1623	4163

Title: DIALYSIS SOLUTIONS WITH REDUCED LEVELS OF GLUCOSE DEGRADATION PRODUCTS

## **COMMISSIONER FOR PATENTS:**

Transmitted herewith is:

Response to Office Action (9 pages); and Return Receipt Postcard

in the above identified application.

- No additional fee is required.
- ☐ A check in the amount of

is attached.

- The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.
  - Charge the amount of
  - Credit any overpayment.
  - Charge any additional fee required.

☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Signature

Dated: October 19, 2005

Robert M. Barrett (30,142)

Customer No.: 29200

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

October 19, 2005

Signature of Person Mailing Carrespondence

Heather Poster

Typed or Printed Name of Person Mailing Correspondence

cc:

## OTPE 4005 OCT 9 1 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Zieske et al. Appl. No.: 10/628,065

Conf. No.: 4163

Filed: July 25, 2003

Title: DIALYSIS SOLUTIONS WITH REDUCED LEVELS OF GLUCOSE

**DEGRADATION PRODUCTS** 

Art Unit: 1623 Examiner: E. Peselev

Docket No.: DI-5924 (BBL No. 112713-429)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## RESPONSE TO OFFICE ACTION

Sir:

In response to the Office Action dated July 21, 2005, Applicants respond as follows:

The Claims are presented in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 8 of this paper.